Fairvalue-Calculator Fairvalue-Calculator
EN DE

Lumosa Therapeutics Co (6535) Fair Value & Analysis

Healthcare · TW · Market cap 17.9B TWD

Price100.00 TWD
Fair Value27.04 TWD
Upside-73.0%
Quality94/100
Evidence: Low Range 20.28 TWD – 33.80 TWD

Analysis

Lumosa Therapeutics Co (6535) currently trades at 100.00 TWD, while our model-based Fair Value estimate is 27.04 TWD — implying the stock looks roughly 73.0% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops drugs for neurological and oncological diseases in Taiwan and the rest of Asia. The company offers Naldebain (LT-1001), an analgesic injection for postoperative pain. It also develops LT3001, which has completed Phase 2b clinical trials for the treatment of acute ischemic stroke; LT6001, which is in pre-clinical trials for the treatment of neurological disorders; and CS028, which is in the pre-clinical stage for the treatment of solid tumors. In addition, the company engages in the investment, new drug development consulting, and service and transfer of techniques activities. The company was formerly known as SunTen Phytotech Co., Ltd. and changed its name to Lumosa Therapeutics Co., Ltd. in June 2014. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -63%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.